PD3-07 CONDITIONAL SURVIVAL ANALYSIS FOR PATIENTS WITH ADRENAL CORTICAL CARCINOMAS: RESULTS FROM POPULATION-BASED DATA

Yuanyuan Qu,Yuandong Zhu,Dingwei Ye
DOI: https://doi.org/10.1016/j.juro.2015.02.294
2015-01-01
Abstract:You have accessJournal of UrologyAdrenal1 Apr 2015PD3-07 CONDITIONAL SURVIVAL ANALYSIS FOR PATIENTS WITH ADRENAL CORTICAL CARCINOMAS: RESULTS FROM POPULATION-BASED DATA Yuanyuan Qu, Yao Zhu, and Dingwei Ye Yuanyuan QuYuanyuan Qu More articles by this author , Yao ZhuYao Zhu More articles by this author , and Dingwei YeDingwei Ye More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2015.02.294AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Surgical excision is essential in the management of adrenal cortical carcinomas (ACC) and offers the best change of cure. The 5-year overall survival (OS) in ACC is ranging from 15% to 84% according to the extension of disease. This is, however, not as informative to patients who have survived for some time. This study aimed to examine the impact of length of survival on future survival probability, otherwise known as the effect of conditional survival (CS), after surgical excision in patients with ACC. METHODS Using population-based Surveillance, Epidemiology, and End Results database (1988–2010), 531 patients with locoregional ACC who underwent surgery were reviewed. Cox proportional hazard models were used to assess the prognostic factors at baseline. CS estimates were calculated in the entire cohort and according to Union for International Cancer Control (UICC) stage. RESULTS Median age of entire cohort was 53 years. Most patients had stage II disease (59%), followed by stage III (21%), IV (15%) and I (6%). Median OS was 66 months and 5-year OS rate was 51.4%. Multivariate analysis showed that age and tumor stage had significant effect on OS (P < 0.01). 1-year OS for the entire cohort at 1, 2, 3, 4, 5 years was 70%, 60.9%, 55%, 51.4% and 48.7%, respectively. CS of an additional year given survival to 1, 2, 3, 4, 5 year was 82.7%, 87%, 90.4%, 93.4% and 94.9%, respectively. Patients who survive >24 months after their initial treatment had improved 1-year CS. The difference between Kaplan-Meier estimates and CS estimates was more pronounced in stage III/IV disease (Figure 1). CONCLUSIONS CS may provide more meaningful life expectancy predictions for survivors of ACC than conventional survival outcomes. Specially, even amongst patients with advanced disease after surgery, a more favorable prognosis can be achieved after surviving for 2 years. © 2015 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 193 Issue 4S April 2015 Page: e83-e84 Advertisement Copyright & Permissions© 2015 by American Urological Association Education and Research, Inc.Metrics Author Information Yuanyuan Qu More articles by this author Yao Zhu More articles by this author Dingwei Ye More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...
What problem does this paper attempt to address?